CODEXIS INC (CDXS) competitors & alternatives
Health Care · NASDAQ
CODEXIS INC (CDXS)'s top competitors and alternatives — its most similar public companies — include BioMarin Pharmaceutical (BMRN), WAVE LIFE SCIENCES LTD (WVE), 4D MOLECULAR THERAPEUTICS INC (FDMT), Revvity (RVTY), ARROWHEAD PHARMACEUTICALS, INC. (ARWR), BENITEC BIOPHARMA INC (BNTC), GENERATE BIOMEDICINES INC (GENB), NURIX THERAPEUTICS INC (NRIX), NOVARTIS AG (NVS), Alnylam Pharmaceuticals (ALNY), GINKGO BIOWORKS HOLDINGS INC CLASS (DNA) and SPRUCE BIOSCIENCES INC (SPRB). These are CODEXIS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CDXS competitors & alternatives
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
-
WAVE LIFE SCIENCES LTDWVEHealth Care
A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex…
$5.74 (as of 2026-07-22) · market cap $1.1B
-
4D MOLECULAR THERAPEUTICS INCFDMTHealth Care
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary…
$10.96 (as of 2026-07-22) · market cap $573M
-
RevvityRVTYHealth Care
Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic…
$110.54 (as of 2026-07-22) · market cap $12.3B
-
ARROWHEAD PHARMACEUTICALS, INC.ARWRHealth Care
A clinical-stage biotechnology company pioneering RNA interference (RNAi) therapeutics to treat a wide array of genetic and chronic diseases by silencing…
$88.70 (as of 2026-07-22) · market cap $13.0B
-
BENITEC BIOPHARMA INCBNTCHealth Care
Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to…
$11.44 (as of 2026-07-22) · market cap $396M
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
GINKGO BIOWORKS HOLDINGS INC CLASSDNAHealth Care
Ginkgo Bioworks engineers biology at scale through lab automation, AI-driven R&D services, and biosecurity infrastructure to help customers develop new…
$7.83 (as of 2026-07-22) · market cap $511M
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
Not quite? Describe exactly what you want →
Peers are CODEXIS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: CODEXIS INC (CDXS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.